ras mutation and expression of the ras‐regulated genes osteopontin and cathepsin L in human esophageal cancer
暂无分享,去创建一个
M. Tsao | F. O'Malley | H. Ozçelik | A. Chambers | A. Casson | S. Wilson | J. A. McCart | Sylvia M. Wilson | J. McCart
[1] J. F. Harris,et al. Osteopontin expression in lung cancer. , 1996, Lung cancer.
[2] Ruggero Montesano,et al. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review , 1996, International journal of cancer.
[3] H. Yamasaki,et al. High frequency of ki‐ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus , 1995, Molecular carcinogenesis.
[4] F. O'Malley,et al. Prognostic value of p53 protein in esophageal adenocarcinoma , 1995, Journal of surgical oncology.
[5] S. Mousses,et al. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] A. Chambers,et al. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell , 1995, Molecular and cellular biology.
[7] A. Chambers,et al. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. , 1994, The Journal of biological chemistry.
[8] A. Craig,et al. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. , 1994, Cancer research.
[9] H. Yamasaki,et al. G→A mutations in p53 and Ha‐ras genes in esophageal papillomas induced by N‐nitrosomethylbenzylamine in two strains of rats , 1994, Molecular carcinogenesis.
[10] A. Chambers,et al. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study. , 1994, Cancer detection and prevention.
[11] D. Denhardt,et al. Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] S. Hirohashi,et al. Possible role of activated ras genes in human esophageal carcinogenesis , 1993, International journal of cancer.
[13] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[14] A. Chambers,et al. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. , 1992, Anticancer research.
[15] A. Chambers,et al. Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras‐transformed NIH 3T3 cells , 1992, Molecular carcinogenesis.
[16] J. Roth,et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. , 1991, Cancer research.
[17] R Montesano,et al. Frequent mutation of the p53 gene in human esophageal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[18] O. Mcbride,et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). , 1990, Genomics.
[19] D. Skinner,et al. Expression of ras oncogene p21 protein in esophageal squamous cell carcinoma , 1990, Journal of surgical oncology.
[20] Marshall W. Anderson,et al. Mutational activation of the cellular Harvey ras oncogene in rat esophageal papillomas induced by methylbenzylnitrosamine. , 1990, Cancer research.
[21] P. Waterhouse,et al. Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins. , 1986, Cancer research.